antibody

(redirected from blocking antibody)
Also found in: Dictionary, Medical, Encyclopedia, Wikipedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Words related to antibody

References in periodicals archive ?
When cells were preincubated with an anti-TLR4 blocking antibody, the stimulatory effect of F.
The cisplatin-treated A549 cells with or without B7-H1 blocking antibody (50 mg/mL, Biolegend) were then added to CFSE-labeled T cells at a T:A549 ratio of 1:2, 1:4, or 1:8.
Abbreviations GD --Graves' disease TSH --thyroid-stimulation hormone TRAb --TSH receptor antibodies MTT --thyroid suppressive therapy ROC --Receiver Operating Characteristic curve MMD --minimum maintenance dose TSAb --thyroid stimulating antibody TBAb --thyroid blocking antibody Rad je primljen 14.
Pre-incubation of THP-1 cells with an integrin [beta]2 blocking antibody did not abolish the effect of late EPCs on IL-1[beta] mRNA production, suggesting that regulation of IL-1[beta] expression in THP-1 cells by late EPCs is independent of integrin [beta]2.
On the contrary, in SW620 cells, the amount of apoptotic cells was not modified by the blocking antibody (Figure 3A).
The novel type of VEGFR-3 blocking antibody has an unprecedented mechanism of action, which was effective even at very high concentrations of the VEGF-C growth factor.
It is also the sole GS component with a single-pass transmembrane domain and a large extracellular segment [38] that is potentially targetable with a blocking antibody. During GS composition, nicastrin represents a structural scaffold for other member proteins to assemble on, while within a functional complex, it executes a substrate recognition role [3,38].
He says the onset of arthritis took two weeks longer in the receptor-antibody-treated mice than in mice not given the blocking antibody.
Under the agreement, Roche will provide its PD-L1 blocking antibody atezolizumab (TECENTRIQ) for use in Phase I/II clinical studies together with Kymab's lead investigational anti-ICOS antibody therapy, KY1044, in patients with advanced solid cancers.
The association of IgG4 with protective activity is related to its function as a blocking antibody or a marker of tolerance induction, resulting in a decreased sensitivity of T cells and consequently in a suppression of the late-phase reactions [37].
A quantitative in vitro study of the chromatographic distribution and immunoglobulin characteristics of human blocking antibody. J Immunol 1968;101: 317-24.